pyrazines has been researched along with Melanoma in 52 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.92) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (36.54) | 29.6817 |
2010's | 29 (55.77) | 24.3611 |
2020's | 3 (5.77) | 2.80 |
Authors | Studies |
---|---|
Deng, JJ; Fan, G; Ge, Y; Huang, J; Liu, L; Song, Z; Xiong, XF | 1 |
Aasen, SN; Bjørnstad, OV; Haan, C; Herdlevær, CF; Hoang, T; Preis, J; Reigstad, A; Rigg, E; Sundstrøm, T; Thorsen, F | 1 |
Bürkel, F; Distel, L; Fietkau, R; Hecht, M; Heinzerling, L; Jost, T | 1 |
Elmquist, WF; Gampa, G; Kim, M; Mladek, AC; Mohammad, AS; Parrish, KE; Sarkaria, JN | 1 |
Abu-Odeh, R; Al-Qawasmeh, RA; Al-Tel, TH; Chouaib, S; El-Awady, R; Saber-Ayad, M; Semreen, MH; Voelter, W | 1 |
Bonkobara, M; Hiroi, T; Ito, K; Iwata, T; Kobayashi, M; Kuroki, S; Kuroki, T; Mori, K; Nakagawa, T; Ono, K; Ozawa, Y; Sasaki, Y; Tetsuka, M; Washizu, T; Yamamoto, H | 1 |
Reisman, SA | 1 |
Brooks, TR; Carson, WE; Dao, TV; Grignol, VP; Hade, EM; Kendra, KL; Kondalasula, SV; Lesinski, GB; Luedke, EA; Markowitz, J; Mundy-Bosse, BL; Olencki, T; Paul, BK | 1 |
Bloomfield, CD; Carson, WE; de la Chapelle, A; Eisfeld, AK; Hoag, KW; Huang, X; Jarvinen, TM; Leffel, B; Marcucci, G; Markowitz, J; Patel, R; Perrotti, D; Santhanam, R; Schwind, S; Walker, CJ | 1 |
Ashton, G; Brognard, J; Carragher, N; Davies, L; Ejiama, S; Fish, L; Frame, M; Fusi, A; Girotti, MR; Hohloch, J; Johnson, L; Lopes, F; Lorigan, P; Macleod, K; Marais, R; Marusiak, AA; McLeary, R; Menard, D; Niculescu-Duvaz, D; Pedersen, M; Preece, N; Sanchez-Laorden, B; Saturno, G; Springer, C; Suijkerbuijk, BM; Viros, A; Whittaker, S; Zambon, A | 1 |
Flaherty, KT | 1 |
Aleksic, T; Asher, R; Bridges, E; Gao, S; Kamdoum, WP; Li, JL; Macaulay, VM; Margison, GP; Middleton, MR; Pfister, SX; Ramcharan, R; Repapi, E; Tanner, J; Watson, AJ; Woodcock, M | 1 |
Baska, F; Boros, S; Dobos, J; Garamvölgyi, R; Illyés, E; Kékesi, L; Kéri, G; Őrfi, L; Sipos, A; Szabadkai, I; Szántai-Kis, C | 1 |
Armstrong, JL; Birch-Machin, MA; Brown, AM; Corazzari, M; Hill, D; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP | 1 |
Bouchard, P; Brown, L; Carson, WE; Chaudhury, AR; Go, MR; Guenterberg, K; Guttridge, DC; Hade, E; Ladner, KJ; Lesinski, GB; Lewis, A; Quimper, M; Raig, ET; Shah, NN; Young, G | 1 |
Erin, N; Yerlikaya, A | 1 |
Armstrong, JL; Birch-Machin, MA; Flockhart, R; Hill, DS; Lovat, PE; Martin, S; Redfern, CP; Simpson, DG; Tonison, JJ | 1 |
Benninger, K; Carson, WE; Kreiner, M; Lesinski, GB; Quimper, M; Young, G | 1 |
Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K | 1 |
Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K | 1 |
Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y | 1 |
Blaskovits, FM; Carson, WE; Chan, AN; Grignol, VP; Guenterberg, KD; Lesinski, GB; Mundy, BL; Nuovo, GJ; Raig, ET; Young, GS; Zimmerer, JM | 1 |
Abken, H; Brinkmann, K; Coutelle, O; Hombach, AA; Kashkar, H; Krönke, M; Mauch, C; Schmidt, P; Seeger, JM; Wagner-Stippich, D; Zigrino, P | 1 |
Blank, JL; Burkhardt, AL; Chen, S; Chen, W; Driscoll, DL; Garcia, K; Gray, J; Hales, P; Leroy, PJ; Lightcap, ES; Lingaraj, T; Liu, XJ; Menon, S; Morgenstern, JP; Peters, T; Pickard, MD; Rabino, C; Rappoli, DM; Ringeling, J; Sappal, DS; Spelman, JJ; Yu, J | 1 |
Anichini, A; Bolognesi, M; Delia, D; Drago, C; Kashkar, H; Lecis, D; Manzoni, L; Mastrangelo, E; Scolastico, C; Seneci, P; Walczak, H | 1 |
Armstrong, JL; Birch-Machin, M; Fulda, S; Harbottle, A; Hill, DS; Hiscutt, EL; Kerr, R; Lovat, PE; Martin, S; Redfern, CP | 1 |
Birch-Machin, MA; Hill, DS; Lovat, PE; Martin, S; Paton, AW; Paton, JC; Redfern, CP | 1 |
Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
Al Sabah, S; Armstrong, JL; Corazzari, M; Ellis, N; Falasca, L; Fimia, GM; Hill, DS; Lovat, PE; Martin, S; Pagliarini, V; Piacentini, M; Redfern, CP | 1 |
Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A | 1 |
Chang, HC; De La Rosa, M; Han, L; Lupov, IP; Oza, K; Pelloso, D; Robertson, MJ; Sahu, RP; Schwartz, A; Travers, JB; Voiles, L | 1 |
Cochran, MC; Eisenbrey, JR; Oum, KL; Wheatley, MA | 1 |
Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H | 1 |
Balivada, S; Basel, MT; Bossmann, SH; Kalita, M; Moore, D; Pyle, M; Rachakatla, RS; Seo, GM; Shinogle, H; Shrestha, TB; Thapa, PS; Troyer, DL; Villanueva, D; Wang, H | 1 |
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H | 1 |
Ahmad, M; Badura, HE; El-Khattouti, A; Ghanjati, F; Haikel, Y; Hassan, M; Porzig, BB; Santourlidis, S; Selimovic, D | 1 |
Birdsell, CA; Crosby, NA; Ernstoff, MS; Poklepovic, A; Ramakrishnan, V; Roberts, JD; Winning, M; Youseffian, L; Youssefian, LE | 1 |
Amiri, KI; Horton, LW; LaFleur, BJ; Richmond, A; Sosman, JA | 1 |
Adjei, AA; Albertini, M; Dawkins, F; Erlichman, C; Fitch, T; Fracasso, PM; Geyer, SM; Lorusso, P; Maples, W; Markovic, SN; Sharfman, W | 1 |
Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J | 1 |
Fernández, Y; Lowe, SW; Miller, TP; Opipari, AW; Rush, JL; Soengas, MS; Steiner, P; Verhaegen, M | 1 |
Bengston, AL; Denoyelle, C; Esteban, JA; Fernández, Y; Miller, TP; Soengas, MS; Tang, WH | 1 |
Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H | 1 |
Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A | 1 |
Chinnaiyan, AM; Fernandez, Y; Gratchouck, V; Jakubowiak, AJ; Nikiforov, MA; Riblett, M; Soengas, MS; Tang, WH; Varambally, S; Verhaegen, M; Zhuang, D | 1 |
Casanova, JM; Dolcet, X; Egido, R; Llobet, D; Llombart, A; Marti, RM; Matias-Guiu, X; Pérez de Santos, AM; Schoenenberger, JA; Soria, X; Sorolla, A; Vilella, R; Yeramian, A | 1 |
Fuchs, SY | 1 |
Chimirri, A; Fenech, G; Grasso, S; Monforte, P | 1 |
Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE | 1 |
Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP | 1 |
Chapman, RA; Doolittle, GC; Flaherty, LE; Hammond, N; Klein, CE; Kraut, EH; Mills, GM; Sondak, VK; Unger, JM; Whitehead, RP | 1 |
8 trial(s) available for pyrazines and Melanoma
Article | Year |
---|---|
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytokines; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrazines; Recombinant Proteins; Treatment Outcome | 2014 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Temozolomide; Treatment Outcome | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Melanoma; Middle Aged; Pyrazines; Radiography; Sarcoma; Treatment Outcome; Young Adult | 2013 |
A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Proteasome Inhibitors; Pyrazines; Skin Neoplasms; Survival Rate; Treatment Failure | 2005 |
CI-980 in advanced melanoma and hormone refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines | 2000 |
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome | 2001 |
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Pyrazines | 2002 |
44 other study(ies) available for pyrazines and Melanoma
Article | Year |
---|---|
Synthesis and evaluation of imidazo[1,2-a]pyrazine derivatives as small molecule Gαq/11 inhibitors against uveal melanoma.
Topics: Cell Line, Tumor; Humans; Melanoma; Pyrazines; Uveal Neoplasms | 2022 |
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Melanoma; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines | 2022 |
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential.
Topics: Cell Death; Cell Line; Cell Line, Tumor; DNA-Activated Protein Kinase; Fibroblasts; Homologous Recombination; Humans; Melanoma; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; TOR Serine-Threonine Kinases; Triazoles | 2020 |
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Dogs; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 3-Ring; Humans; Madin Darby Canine Kidney Cells; Male; Melanoma; Mice; Mice, Knockout; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Pyrazines; Pyrimidines | 2019 |
Tandem multicomponent reactions toward the design and synthesis of novel antibacterial and cytotoxic motifs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Melanoma; Pyrazines; Pyridines | 2013 |
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
Bortezomib: a therapeutic resource for the veterinary oncologist?
Topics: Animals; Boronic Acids; Bortezomib; Dog Diseases; Melanoma; Melanoma, Cutaneous Malignant; NF-kappa B; Proteasome Inhibitors; Pyrazines; Signal Transduction; Skin Neoplasms | 2013 |
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes; Computational Biology; Core Binding Factor Alpha 2 Subunit; Cytogenetics; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Introns; Leukemia, Myeloid, Acute; Male; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Proteins; NF-kappa B; Phenotype; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Experimental; Mice; Mice, Nude; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; src-Family Kinases; Xenograft Model Antitumor Assays | 2015 |
Effectively targeting CRAF: rational serendipity targeting SRC?
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; src-Family Kinases | 2015 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Breaks, Double-Stranded; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrazines; Receptor, IGF Type 1; Survival Analysis; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Molecular Structure; Pyrazines; Pyridines; Structure-Activity Relationship | 2016 |
Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacitracin; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Enzyme Inhibitors; Fenretinide; Humans; Melanoma; Oxidative Stress; Protein Disulfide-Isomerases; Pyrazines; Treatment Outcome; Tumor Cells, Cultured | 2008 |
IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Caspase 3; Caspase 8; Fas-Associated Death Domain Protein; Humans; Interferon-alpha; Kidney Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2008 |
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum; Female; Fenretinide; G2 Phase; Humans; Ki-67 Antigen; Melanoma; Mice; Pyrazines | 2009 |
Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; Interferon Type I; Janus Kinases; Leukocytes, Mononuclear; Melanoma; Phosphorylation; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; Signal Transduction; STAT1 Transcription Factor; Up-Regulation | 2009 |
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured | 2009 |
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Interferons; Interleukins; Janus Kinase 1; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Signal Transduction; Skin Neoplasms; STAT Transcription Factors; Temozolomide | 2010 |
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Combined Modality Therapy; Enzyme Activation; Granzymes; Humans; Immunotherapy, Adoptive; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Melanoma; Mitochondria; Mitochondrial Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Cell Surface; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Colonic Neoplasms; DNA Damage; Gene Knockdown Techniques; HCT116 Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Protease Inhibitors; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrazines; Ribosomes; RNA, Small Interfering; TOR Serine-Threonine Kinases; Transfection | 2010 |
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Topics: Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 8; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Interactions; Drug Synergism; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondrial Proteins; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Fenretinide; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Vitro Techniques; Male; Melanoma; Middle Aged; Mutation; Nevus, Pigmented; Proto-Oncogene Proteins B-raf; Pyrazines; RNA, Small Interfering; Skin Neoplasms; Stress, Physiological; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Targeting GRP78 to enhance melanoma cell death.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Fenretinide; Heat-Shock Proteins; Humans; Melanoma; Pyrazines; RNA, Small Interfering; Unfolded Protein Response | 2010 |
Oncogenic B-RAF signaling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biphenyl Compounds; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Female; Fenretinide; Humans; Luminescent Proteins; Melanoma; Mice; Microscopy, Fluorescence; Microtubule-Associated Proteins; Nitrophenols; Piperazines; Proto-Oncogene Proteins B-raf; Pyrazines; RNA Interference; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Carmustine; Cells, Cultured; Drug Interactions; Etoposide; Flow Cytometry; Gene Expression; Humans; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Lymphoma; Melanoma; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Pyrazines; RNA Stability; Skin Neoplasms; STAT4 Transcription Factor; Ubiquitin | 2011 |
Cellular signal transduction can be induced by TRAIL conjugated to microcapsules.
Topics: Annexin A5; Apoptosis; Boronic Acids; Bortezomib; Capsules; Cell Line, Tumor; Contrast Media; Doxorubicin; Flow Cytometry; Humans; Lactic Acid; Melanoma; Membranes, Artificial; Particle Size; Polyesters; Polymers; Pyrazines; Signal Transduction; Staining and Labeling; TNF-Related Apoptosis-Inducing Ligand; Ultrasonics | 2012 |
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome | 2012 |
Stem cell-based photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Cell Survival; Female; Fetal Blood; Imidazoles; Luciferases; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neural Stem Cells; Oxidation-Reduction; Photochemotherapy; Photosensitizing Agents; Plasmids; Protoporphyrins; Pyrazines; Rats; Stem Cell Transplantation; Stem Cells; Transfection | 2012 |
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured | 2013 |
Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calcium; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; HSP70 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Membrane Potential, Mitochondrial; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
News & views in ... Immunotherapy.
Topics: Allergens; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cattle; Female; Glycogen Storage Disease Type II; Human papillomavirus 16; Human papillomavirus 18; Humans; Hypersensitivity; Immunotherapy; Leukotriene B4; Melanoma; Milk; Milk Proteins; Papillomavirus Infections; Pyrazines; Receptors, Leukotriene B4; Skin Neoplasms; Tumor Escape; Uterine Cervical Neoplasms; Viral Vaccines | 2012 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Gene Expression; Humans; Melanoma; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Pyrazines; Temozolomide | 2004 |
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2005 |
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cisplatin; Cytochromes c; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; Up-Regulation; Xenograft Model Antitumor Assays | 2005 |
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Binding, Competitive; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Drug Antagonism; Fibroblasts; Free Radicals; Humans; Immunoblotting; Kinetics; Leupeptins; Melanocytes; Melanoma; Membrane Potentials; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Skin; Time Factors | 2006 |
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine | 2006 |
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles | 2007 |
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Boronic Acids; Bortezomib; Drug Design; E2F1 Transcription Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanocytes; Melanoma; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Interference; RNA, Messenger; Skin Neoplasms; Transcriptional Activation; Tumor Suppressor Protein p53 | 2007 |
Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Female; Humans; Male; Melanoma; Protease Inhibitors; Pyrazines; Skin Neoplasms; Treatment Outcome | 2008 |
MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines | 2008 |
[Compounds with presumable antitumor activity. III. 1-Substituted N,N'-di-2-pyrimidinyl (or pyrazinyl)methylenediamine].
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Diamines; Female; Leukemia L1210; Leukemia P388; Mammary Neoplasms, Experimental; Melanoma; Mice; Ovarian Neoplasms; Pyrazines; Pyrimidines; Rats | 1984 |